Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 81

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 81
---
on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income
statement. A key input in the valuation of the instrument is the Company share price.

Details of the warrants are as follows:

July 2024 warrants

In July 2024 the Company issued213,188Series J ADS Warrants and213,188Series K warrants as part of the Registered Direct Offering and Concurrent Private Placement in the
US.

May 2024 warrants

In May 2024 the Company issued94,358Series G ADS Warrants and147,805Series H warrants as part of the Warrant Inducement in the US.

December 2023 warrants

In December 2023 the Company issued119,998Series E ADS Warrants and119,996Series F ADS Warrants as part of the Registered Offering in the US. The Series F warrants expired
on 23 December 2024.

May 2023 warrants

In June 2023 the Company issued11,059Series D ADS Warrants as part of a registered direct offering and private placement in the US after securing shareholder approval.

May 2020 warrants

In May 2020 the Company issued30ADS
warrants as part of a registered direct offering in the US.

October 2019 warrants

In October 2019 the Company issued15ADS warrants as part of a registered direct offering in the US.

Warrant re-price

On 22 July 2024 the Company agreed to
reduce the exercise price of the Company’s existing Series E warrants, Series G warrants and Series H warrants held by those investors
who participated in the Registered Direct Offering and Concurrent Private Placement to $25.00 per ADS.

  Number and original price of warrants have been adjusted to reflect                                                                
  the share consolidation and ratio change of ADS’s to ordinary shares that occurred on 24 March 2023 and the ratio change of ADS’s  
  to ordinary shares on 26 September 2022, 5 July 2023 and 4 October 2024.                                                           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

DARA warrants and share options

The Group also assumed fully vested
warrants and share options on the acquisition of DARA Biosciences, Inc. (which took place in 2015). The number of ordinary shares to be
issued when exercised is fixed, however the exercise prices are denominated in US Dollars. The warrants are classified equity